Action NXTCL NEXTCELL PHARMA AB
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues NextCell Pharma AB

Actions

NXTCL

SE0009723125

Temps Différé Nasdaq Stockholm
Autres places de cotation
 16:09:50 17/07/2024 		Varia. 5j. Varia. 1 janv.
1,52 SEK -0,65 % Graphique intraday de NextCell Pharma AB +16,92 % -42,21 %
12/06 Nextcell Pharma AB reçoit une recommandation positive du comité de surveillance des données de sécurité pour l'étude Protrans-Young CI
28/05 NextCell Pharma AB annonce qu'un traitement unique avec ProTrans démontre un effet thérapeutique à long terme sur 5 ans CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !
Inscription 100% Gratuite
NextCell carries out a directed issue of units to guarantors in connection with the completed rights issue
NextCell's rights issue oversubscribed
The paediatric diabetes study gets the green light to treat the age group 7 - 11 years
Nextcell Pharma AB Receives Positive Recommendation from Data Safety Monitoring Board for Protrans-Young Study
The Board of Directors and management sign in addition to subscription commitments
NextCell publishes supplement to the prospectus regarding the rights issue
Cellaviva becomes an independent company under NextCell Pharma
NextCell procures top guarantee in ongoing rights issue
The subscription period in NextCell's rights issue commences today
NextCell publishes prospectus in connection with the rights issue of units of approximately SEK 40.1 million
Single treatment with ProTrans demonstrates long-term therapeutic effect over 5 years
NextCell Pharma AB Announces Single Treatment with ProTrans Demonstrates Long-Term Therapeutic Effect over 5 Years
Bulletin from the Extraordinary General Meeting of NextCell Pharma AB (publ)
Nextcell Pharma AB Elects Hans-Peter Ekre as New Chairman of the Board
NextCell publishes its Interim Report 2 2023/2024
NextCell Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024
Notice of Extraordinary General Meeting in NextCell Pharma AB (publ)
The Board of Directors of NextCell resolves on a rights issue of units of approximately SEK 40.1 million, subject to approval by an Extraordinary General Meeting
NextCell's daughter company Cellaviva granted permission to handle amniotic tissue
NextCell Pharma AB Announces Swedish Health and Social Care Inspectorate Grants Their Cellaviva Tissue Establishment Permission to Handle Amniotic Tissue
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NXTCL
  4. Actualités NextCell Pharma AB
  5. Autres langues